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Heterologous Expression of a Novel 
Drug Transporter from the Malaria 
Parasite Alters Resistance to 
Quinoline Antimalarials
Sarah M. Tindall1, Cindy Vallières1, Dev H. Lakhani1, Farida Islahudin2, Kang-Nee Ting3 & 
Simon V. Avery  1
Antimalarial drug resistance hampers effective malaria treatment. Critical SNPs in a particular, putative 
amino acid transporter were recently linked to chloroquine (CQ) resistance in malaria parasites. Here, 
we show that this conserved protein (PF3D7_0629500 in Plasmodium falciparum; AAT1 in P. chabaudi) 
is a structural homologue of the yeast amino acid transporter Tat2p, which is known to mediate quinine 
uptake and toxicity. Heterologous expression of PF3D7_0629500 in yeast produced CQ hypersensitivity, 
coincident with increased CQ uptake. PF3D7_0629500-expressing cultures were also sensitized to 
related antimalarials; amodiaquine, mefloquine and particularly quinine. Drug sensitivity was reversed 
by introducing a SNP linked to CQ resistance in the parasite. Like Tat2p, PF3D7_0629500-dependent 
quinine hypersensitivity was suppressible with tryptophan, consistent with a common transport 
mechanism. A four-fold increase in quinine uptake by PF3D7_0629500 expressing cells was abolished 
by the resistance SNP. The parasite protein localised primarily to the yeast plasma membrane. Its 
expression varied between cells and this heterogeneity was used to show that high-expressing cell 
subpopulations were the most drug sensitive. The results reveal that the PF3D7_0629500 protein can 
determine the level of sensitivity to several major quinine-related antimalarials through an amino acid-
inhibitable drug transport function. The potential clinical relevance is discussed.
The fight for malaria eradication continues apace, but there were still over 200 million cases of this devastating 
parasitic disease in 20151,2. In the absence of a commercially available vaccine, artemisinin combination therapies 
(ACTs) are the current main line of antimalarial defence in most countries. Quinoline antimalarials (commonly in 
combination with an antibiotic) are also recommended as first-line malaria treatments during early pregnancy and 
second line treatment for uncomplicated malaria cases, but remain first line drugs in many African countries3–5. 
Furthermore, quinoline derivatives such as amodiaquine, mefloquine and lumefantrine are currently used in rec-
ommended ACTs. Chloroquine was one of the most effective drugs ever produced and, along with primaquine, 
remains a drug of choice for treating Plasmodium vivax malaria5. Quinine (QN) has historically been a mainstay 
of the antimalarial drug repertoire but the wider use of QN is now hampered by poor compliance, the prevalence 
of adverse drug reactions and the availability of alternative antimalarials3.
One strategy in the battle against malaria is the identification of drug resistance mechanisms in the parasite. 
Identifying genetic changes that confer drug resistance helps the spread of resistance to be tracked and can allow 
appropriate antimalarial drug therapy to be tailored6,7. In addition, knowledge of the genetic basis for resistance 
can give insight to the mechanism of action of a drug, informing improved drug design or treatment strategies. 
Membrane transporters provide a classic example of proteins that can mediate drug resistance or sensitivity8,9. In 
the malaria parasite most lethal to humans, Plasmodium falciparum, multiple transporters have been associated 
with altered sensitivity to quinoline antimalarials including PfCRT, PfNHE1, PfMDR1 and PfMRP10. PfCRT is 
the most widely reported of these, localized to the parasite digestive vacuole and in which SNPs are commonly 
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associated with chloroquine resistance11. Quinine resistance took over 200 years to emerge, but this is in strik-
ing contrast to other antimalarial drugs. Widespread resistance to chloroquine was evident just 40 years after 
its introduction. Quinine resistance is only found in some malaria-endemic areas and is usually low level3. The 
incidence of chloroquine resistance may sometimes be reversed relatively quickly when chloroquine treatment is 
discontinued12,13. Therefore, in the face of rising ACT resistance14 quinolines could in some regions continue to 
provide a valid alternative in the future.
One problem with characterisation of drug transport and resistance mechanisms in malaria parasites is 
that not all of the relevant species are easy to cultivate in the laboratory or to manipulate genetically, although 
improvements are being made including with P. falciparum15,16. Model organisms may be exploited as an alterna-
tive. The yeast Saccharomyces cerevisiae is an especially powerful model of eukaryotic cells that has been widely 
exploited for antimalarial drug discovery or mode-of-action studies17–21. Yeast has an unparalleled toolset for 
genetics and synthetic biology, and is a valuable host for heterologous expression of functional Plasmodium spp. 
proteins22–24. Previously, yeast genomic tools were used to reveal a novel mechanism of quinoline drug action, 
centred on cellular tryptophan (Trp) starvation. This action results from competition between drug and trypto-
phan for the high affinity yeast tryptophan/tyrosine transporter, Tat2p20. Subsequently, the link between trypto-
phan and quinine action was successfully extended to malaria patients, where it was found that individuals with 
higher plasma tryptophan levels had a low incidence of adverse reactions to quinine25. Furthermore, quinine per-
turbs biosynthesis and function of the major neurotransmitter serotonin, a metabolic product of tryptophan19,26.
In the present work, the earlier findings with yeast are exploited to test function of a Tat2p structural homo-
logue that we identify in Plasmodium spp. It transpires that this homologue is a putative amino acid transporter in 
which SNPs were previously linked to chloroquine resistance in malaria parasites27,28. A recent attempt at charac-
terisation by heterologous expression in Xenopus laevis oocytes did not produce detectably-functional protein29. 
Here we successfully apply a yeast heterologous expression system to show that the parasite protein mediates 
uptake of quinoline drugs so altering the level of drug resistance. The evidence suggests a new quinoline-drug 
transport protein, which may help explain the protein’s association with drug resistance of the parasite.
Results
The P. falciparum orthologue of P. chabaudi aat1 and yeast TAT2 mediates chloroquine uptake 
and toxicity. The high affinity yeast tryptophan transporter Tat2p was previously found to transport quinine 
into cells, leading to quinine toxicity20. Here, standard BLAST searches for homologues of yeast Tat2p among 
Plasmodium spp. revealed no hits. However, an HHPRED homology search against Tat2p based on predicted 
secondary structures (see Methods) identified the putative amino acid transporter PF3D7_0629500 from P. fal-
ciparum (PlasmoDB: PFF1430c, Uniprot ID:C6KTD0, E-value 1.8e-17, Probability 99.87; note that E-value < 1 
and probability > 95 indicate statistically significant homology: https://toolkit.tuebingen.mpg.de/hhpred/help_
ov#evalues) (Supplementary Fig. S1). PF3D7_0629500 was 82nd in a ranking of the proteins most-homologous 
to Tat2p among all available proteomes in HHPRED, and was the most significant homologue from P. falci-
parum. HHPred performs alignments of a protein amino acid sequence to secondary structure databases. No 
such database currently exists for certain species, such as the rodent parasite P. chabaudi, therefore we could 
not search Tat2p against all parasite species. However, PF3D7_0629500 is a known homologue of AAT1 from 
P. chabaudi, and a SNP in the aat1 gene was previously linked with parasite resistance to chloroquine, a quinine 
derivative27. SNPs in PF3D7_0629500 have also been associated with chloroquine resistance in P. falciparum28. 
Considering the evidence collectively, we hypothesized that the parasite protein may have a chloroquine and/or 
quinine transport function, resulting in toxicity if expressed heterologously in yeast. To test this, a codon opti-
mised construct of the PF3D7_0629500 ORF was cloned into the pCM190 expression vector. For heterologous 
expression of the parasite protein we capitalised on the availability of the yeast trp1Δ background. This strain is 
defective for tryptophan biosynthesis, similar to the parasite, and the strain’s dependency on exogenous trypto-
phan gives more sensitive detection of sensitivity to quinoline antimalarials20. Expression of PF3D7_0629500 in 
trp1Δ yeast conferred a chloroquine hypersensitivity phenotype (Fig. 1A). The cell doubling-time in the presence 
of CQ was ˃4-fold longer for cells expressing the parasite protein than empty vector control. In the absence of 
CQ, PF3D7_0629500 expression alone caused a small slowing of growth but the inhibitory effect attributable 
specifically to CQ remained considerably greater in these cells than in the empty vector control. To test whether 
the chloroquine sensitivity of PF3D7_0629500-expressing cells was related to increased chloroquine uptake, the 
chloroquine probe LynxTag-CQ™ was used to measure cellular chloroquine accumulation with flow cytometry. 
Chloroquine accumulation plateaued from ∼10 min. After 15 min, PF3D7_0629500-expressing cells had accu-
mulated ∼38% more drug than empty-vector control cells (p < 0.05, Student’s t-test, one-tailed) (Fig. 1B). The 
results are consistent with the hypothesis that PF3D7_0629500 mediates elevated uptake of chloroquine, leading 
to drug hyper-sensitivity.
Complementation of yeast Tat2 and tryptophan-sensitivity of PF3D7_0629500 activity. The 
trp1Δ background used above, necessary to detect Tat2-suppressible quinoline sensitivity in yeast, was not suit-
able for testing complementation of Tat2 function by PF3D7_0629500 because a trp1Δ/tat2Δ deletant is invi-
able20,30. However, decreased uptake of quinine was previously demonstrated in the tat2Δ single-deletant20,30. 
Therefore, we used this phenotype to test complementation of Tat2 function by PF3D7_0629500. We used an 
assay based on quinine absorbance at 350 nm31, which produced a linear relationship over a range of quinine con-
centrations relevant to our assay (Supplementary Fig. S2A) and which demonstrated time-dependent saturation 
of uptake by cells (Supplementary Fig. S2B). The tat2Δ deletion mutant accumulated ∼75% less quinine than the 
wild type yeast (Fig. 2). This impairment of uptake was fully rescued by expression of the parasite protein (which 
also produced increased quinine uptake in the wild type yeast background). Previously, quinine sensitization 
mediated by the yeast tryptophan-permease Tat2 was shown to be suppressible by added tryptophan20. Here, 
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inclusion of tryptophan (3 mM) significantly decreased PF3D7_0629500-dependent quinine uptake, measured 
in the tat2Δ background (Fig. 2). Therefore, PF3D7_0629500 could replace the tryptophan-suppressible quinine 
uptake activity of its yeast structural homologue.
Sensitization to several quinoline antimalarials is suppressible with the T162E SNP or trypto-
phan. We introduced a T162E mutation to PF3D7_0629500, which corresponded to the SNP previously linked 
to chloroquine resistance in P. chabaudi27. Furthering that association described in the parasite, yeast cells express-
ing the mutant construct were considerably more resistant to chloroquine than cells expressing the wild-type par-
asite protein. That is, introduction of the T162E SNP rescued CQ hypersensitivity of PF3D7_0629500-expressing 
cells (Fig. 3A). The SNP also rescued the mildly-slowed growth of the PF3D7_0629500-expressing cells seen in 
the absence of drug. The SNP version of the parasite gene was expressed at least as strongly in yeast as the wild 
type version. This was shown by qRT-PCR (Fig. 3B), and by measurement of expressed protein levels with western 
blotting or flow cytometry (Supplementary Fig. S3). (There was also no discernible difference in localization of 
the two versions of the protein; see below).
We tested yeast expressing PF3D7_0629500 against several related drugs. As observed with chloroquine, 
PF3D7_0629500 expression conferred hypersensitivity to amodiaquine (weakest phenotype), mefloquine 
and quinine (strongest phenotype). This indicates that the parasite protein determines sensitivity to multiple 
Figure 1. Expression of PF3D7_0629500 increases chloroquine uptake and toxicity. (A) Yeast trp1Δ cells 
transformed with pCM190 vector, either empty (ev) or containing the PF3D7-0629500 ORF (Pf protein), were 
grown either with or without 1 mM chloroquine (CQ) (1 mM CQ was used in order to elicit yeast growth effects 
in the present assay system). Cell doubling times (right panel) were calculated from the exponential growth 
phase and the relevant treatments are as indicated on the panel. (B) Yeast trp1Δ cells transformed as in (A) were 
incubated in the presence of 0.4 mM chloroquine spiked with 20 µM LynxTag-CQ™. Cellular LynxTag-CQ™ 
was determined at intervals with flow cytometry, and cellular autofluorescence subtracted. AU, arbitrary units. 
All values are means ± SEM from three independent determinations. ****, p < 0.0001 according to multiple 
comparisons (with Tukey correction) by two way ANOVA.
Figure 2. Complementation of yeast Tat2 and tryptophan-sensitivity of PF3D7_0629500 activity. Wild type or 
tat2Δ yeast cells transformed with pCM190 vector, either empty (ev) or containing the PF3D7-0629500 ORF 
(Pf protein), were incubated for 20 min with 4 mM quinine either with or without 3 mM tryptophan (Trp). 
NaOH (6 mM) was included in all incubations to balance NaOH carry-over from tryptophan stock solution 
(NaOH had a small stimulatory effect on measured quinine uptake). Quinine analysis in cell lysates was 
according to absorbance determinations at 350 nm, normalised for cell numbers determined just before lysis, 
with subtraction of background (minus-quinine). *p < 0.05; **p < 0.01; ****p < 0.0001; according to multiple 
comparisons (Sidak’s test) by two way ANOVA.
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quinolines. In all cases, the SNP corresponding to that identified previously in the parasite reversed the sensi-
tivity phenotypes (Fig. 3A). IC50 values were derived from growth rate data at varying doses of the drugs which 
gave the strongest phenotypes above. For cells expressing empty vector, PF3D7_0629500 or the SNP construct, 
respectively, IC50 values were 3.56, 2.92 or 3.42 mM for quinine and 0.694, 0.435 or 1.037 mM for chloroquine. 
(In the case of chloroquine, cells expressing the T162E SNP construct were even more resistant to drug than cells 
expressing empty vector.) Previously, as with quinine uptake (above), quinine sensitization mediated by the yeast 
Tat2 was shown to be suppressible by tryptophan20. Here, inclusion of tryptophan in the medium also suppressed 
PF3D7_0629500-mediated sensitization to quinine (Fig. 4), further supporting a similar competition between 
drug and amino acid at this proposed transporter from the parasite.
Relationship between quinine uptake, quinine sensitivity and membrane-localization of 
PF3D7_0629500 in individual cells. Quinine uptake was assayed in the trp1Δ yeast background (versus 
tat2Δ background in Fig. 2 above) so we could test whether quinine sensitization (Fig. 3A) was correlated with 
increased drug uptake in PF3D7_0629500-expressing cells, as was the case with chloroquine (Fig. 1). A rapid 
(≤30 s) initial association of quinine with cells (probably reflecting non-specific cell surface binding) was fol-
lowed by continued accumulation of the drug in the PF3D7_0629500-expressing culture, but not in the empty 
vector control (Fig. 5A). After 60 min, cells expressing the parasite protein had accumulated ∼4-fold more drug. 
This increased uptake was abrogated by introduction of the T162E SNP (Fig. 5B). The data were consistent with 
the suggestion that increased drug uptake in PF3D7_0629500-expressing cells causes their quinine sensitivity.
Yeast Tat2p is a plasma membrane-localized transport protein32. In P. falciparum, PF3D7_0629500 has been 
reported to localize to the digestive vacuole membrane, observed using a fluorescent reporter fusion construct, 
in keeping with its putative function as an amino acid transporter33. To localize PF3D7_0629500 in yeast we 
expressed a GFP tagged version of the protein in the tat2Δ yeast background. Consistent with a transport func-
tion, the protein localized primarily to the yeast plasma membrane, co-localizing precisely with the membrane 
stain FM4-64 (a short FM4-64 staining time was used to restrict staining to the plasma membrane34) (Fig. 6A). 
There was no apparent difference in localization of the PF3D7-0629500 protein versus the same protein carrying 
Figure 3. Sensitization to several quinoline antimalarials by PF3D7_0629500 expression and reversal with the 
T162E SNP. (A) Yeast trp1Δ cells transformed with pCM190 vector, either empty (ev) or expressing PF3D7-
0629500 (Pf protein) or the same protein carrying the T162E SNP (Pf-T162E), were cultured with either 1 mM 
chloroquine (CQ), 1 mM amodiaquine (AQ), 25 μM mefloquine (MQ) or 3 mM quinine (QN). Mean data 
are shown from at least three independent experiments ± SEM. (B) RNA was extracted from wild type yeast 
transformed as in (A) and mRNA corresponding to the wild type PF3D7-0629500 ORF or SNP (T162E) version 
was analysed with qRT-PCR, performed in triplicate for each condition. The same amount of RNA extract 
was used for each reaction. There was not a significant difference (ns, according to Student’s t-test, two tailed) 
between the conditions either when compared by raw counts (as shown) or after normalization against ACT1 
mRNA. au, arbitrary units.
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the T162E SNP. The PfCRT transporter of the parasite’s digestive-vacuole also localizes to the plasma mem-
brane when expressed in yeast24. Unexpectedly, there was visible heterogeneity between individual cells in their 
expression-level and localization of the protein: high-expressing cells are indicated by arrows, while comparison 
with the FM4-64 panels highlights certain cells that showed little or no PF3D7_0629500-associated GFP flu-
orescence (Fig. 6A). Heterogeneity of gene expression, protein localization or other phenotype between indi-
vidual cells within genetically-uniform populations is described in other systems35–37. Here, we exploited this 
phenomenon to interrogate further the relationship between PF3D7_0629500 expression-level and drug sensi-
tivity. Again we exploited the trp1Δ background to help discern drug sensitivity. Heterogeneity in expression of 
PF3D7_0629500-GFP was quantifiable with flow cytometry, which indicated a broad non-normal distribution of 
cell fluorescences extending to almost two orders of magnitude greater than the mode cell-fluorescence (Fig. 6B). 
The > 100-fold total variation in expression level was comparable to that of one of the most variably expressed 
yeast proteins (a virulence factor of Candida glabrata) reported to date38. Cell subpopulations were gated by 
their level of GFP fluorescence (Fig. 6B), then FACS sorted into four cell suspensions which were each assayed 
independently for quinine resistance. Quinine resistance was progressively eroded with increasing expression 
of PF3D7_0629500-GFP (Fig. 6C). The highest expressing fraction of cells showed no growth at 2 mM quinine. 
Figure 4. Sensitization to quinine in PF3D7_0629500-expressing cells is tryptophan suppressible. Yeast trp1Δ 
cells transformed with pCM190 vector, either empty (ev) or expressing PF3D7-0629500 (Pf protein), were 
cultured as specified either with or without 3 mM quinine and/or 1 mM tryptophan (Trp). Cell doubling times 
were calculated during the exponential phase of growth. Mean data are shown from at least three independent 
experiments ± SEM. ****p < 0.0001 according to multiple comparisons (with Tukey correction) by two way 
ANOVA.
Figure 5. Increased quinine uptake in drug-sensitive PF3D7_0629500-expressing cells and reversal with the 
T162E SNP. (A) Yeast trp1Δ cells transformed with vector pCM190, either empty (ev) or expressing PF3D7-
0629500 (Pf protein), were cultured with 4 mM quinine for the indicated time intervals before harvesting and 
lysis. Quinine analysis was as described in the Fig. 2 legend. (B) Yeast trp1Δ cells transformed with vector 
pCM190, either empty (ev), or expressing PF3D7-0629500 (Pf protein) or the same protein carrying the T162E 
SNP (Pf-T162E), were cultured for 20 min with 4 mM quinine before analysis of cellular quinine. Values are 
means ± SEM from three independent determinations. ***, p < 0.001 according to multiple comparisons (with 
Tukey correction) by two way ANOVA.
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In contrast, the lowest expressing cells retained > 80% outgrowth at 2 mM quinine, and ∼10% outgrowth at 
2.5 mM quinine. Results for medium expression-level populations supported this trend, albeit a little more vari-
able between replicates. Therefore, reinforcing the observations with bulk cell populations (Fig. 3A), variation in 
single-cell expression level of PF3D7_0629500 affects the drug sensitivities of individual cells. Such variation itself 
can have important implications, as discussed further below.
Discussion
Previously it was found that, in yeast, quinine is specifically transported via the high-affinity aromatic amino 
acid transporter Tat220. The present study extrapolated this work to the Plasmodium parasite. The major finding 
from heterologous expression studies with PF3D7_0629500, a Tat2 structural-homologue identified from P. fal-
ciparum, was that the parasite protein determines quinine and chloroquine uptake and resistance when expressed 
in yeast. This homologue could not be identified using a standard BLAST search but was found with the HHPred 
tool which uses predicted secondary structures. Protein secondary structures diverge at a slower rate than amino 
acid sequence and so can help to identify more distant homologues39,40.
The protein that is the focus of this work has previously been associated with quinoline resistance in the par-
asite. PF3D7_0629500 was identified by transcriptome profiling as one of only 45 genes differentially expressed 
between chloroquine-sensitive and -resistant mutants of P. falciparum41. Moreover, a non-synonymous SNP in 
AAT1 (the PF3D7_0629500 homologue of P. chabaudi) was a key determinant of chloroquine resistance in lab-
oratory evolved parasites27, and PF3D7_0629500 was recently associated with chloroquine resistance in P. falci-
parum by genome-wide association28. However, the protein has not been subject to detailed study and its function 
is not previously established. Function could not be detected following heterologous expression in Xenopus laevis 
oocytes29, in contrast to the yeast expression system described here. Reasons for this difference may include 
differences in protein folding or localization in the two expression systems. Reported vacuolar-membrane local-
ization of the protein in the parasite translated into plasma membrane localization in yeast (see below), which 
was effective as the protein was functional. Yeast is well documented as a suitable host for heterologous expres-
sion of functional Plasmodium spp. proteins22–24. The PF3D7_0629500 protein is expressed throughout the par-
asite intraerythrocytic cycle, at which most current antimalarials act42,43, and is designated a putative amino acid 
transmembrane transporter based on sequence similarity. The protein has been reported to be expressed at the 
Figure 6. Heterogeneous expression of PF3D7_0629500 at the yeast plasma membrane determines individual-
cell drug sensitivity. (A) Yeast tat2Δ cells expressing GFP-tagged PF3D7-0629500 (Pf protein) or Pf-T162E 
from vector pCM190 were stained with FM4-64 and examined by fluorescence microscopy. The fields of view 
shown are representative of several observed. Merged images (GFP in green, FM4-64 marker in magenta) are 
shown, as are the individual channels. Intensity line profiles along the lines (a, b, c, d) shown in the merged 
images are presented in the lower panels. Arrows indicate the high-expressing cells. au, arbitrary units. (B) Yeast 
trp1Δ cells expressing GFP-tagged PF3D7-0629500 were sorted into low (L), medium-low (ML), medium-high 
(MH) and high (H) -expressing cell subpopulations, according to GFP fluorescence; > 1,000 cells were sorted 
from each subpopulation. (C) Sorted cell subpopulations (B) were spread plated to YPD agar supplemented 
or not with quinine as indicated. Colony forming units (CFUs) were enumerated after 4 d incubation and 
expressed as a percentage of CFUs observed for the same cell subpopulation on minus-quinine control plates. 
Values are means ± SEM from three independent experiments.
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parasite’s digestive vacuole membrane33. Heterologous expression of the GFP tagged version in yeast gave local-
ization primarily to the plasma membrane, providing a convenient system for assaying transport function via 
analysis of whole-cell drug contents after simple cell separation from medium.
The localization information helps rationalise the effects of the protein on drug resistance. In the parasite, 
PF3D7_0629500 is likely to mediate transport of a wide range of amino acids or small peptides from the parasite’s 
digestive vacuole, where haemoglobin is digested42,44. Such movement down the concentration gradient from vac-
uole to cytoplasm is consistent with a facilitated diffusion transport mechanism, as occurs in the yeast homologue 
Tat2. This is further supported by suggestions that PF3D7_0629500-mediated drug transport is passive, unaffected 
by incubation at 4 C or treatment with the protonophore CCCP (S. Tindall and S.V. Avery, unpublished data). It 
follows that, according to its localization, PF3D7_0629500 would facilitate transport of drug (down the concentra-
tion gradient) either from cytoplasm to vacuole in the parasite, or from extra- to intra-cellular in yeast (Fig. 7). In 
both cases, this represents transport of drug to its anticipated site of action (different in yeast and parasite) and is in 
keeping with the drug-sensitivity or -resistance phenotypes seen, respectively, with expression of the wild type or 
SNP (loss of drug transport) versions of the protein in yeast (present data) and parasite27. The SNP introduced here 
corresponded to that found in the parasite-resistance study and which, we showed, impairs drug-transport func-
tion. The T162E SNP creates a more negative charge in a conserved region near the start of a transmembrane helix; 
a very similar effect to that of the K76T SNP in PfCRT which confers CQ resistance27, discussed further below.
As with the yeast Tat2p transporter20, PF3D7_0629500-dependent quinine sensitivity was suppressible with 
tryptophan. This suggests that as in yeast, the drug competes for uptake with tryptophan, a proposed natural sub-
strate of the parasite protein. Such competition may be less relevant where drug and amino acid are moving down 
concentration gradients in opposite directions. Nonetheless, where it does occur, competition can be ascribed 
to the structural similarity of tryptophan and quinine, a drug that is derived enzymatically from tryptophan45. 
Competition between quinine and tryptophan also raises the possibility that quinine displaces the essential amino 
acid intracellularly, e.g. during metabolism or protein synthesis20. Tryptophan depletion arising in this way has 
been proposed to account for certain of the drug’s adverse effects in quinine-treated malaria patients25. It cannot 
be discounted that a similar tryptophan-depletion mechanism could contribute to quinine action in the parasite.
There was heterogeneity between cells in the level of GFP tagged PF3D7_0629500 expression in yeast. Such 
heterogeneity underscores how population averaged measurements can misrepresent the activities relevant to any 
individual cell46. Phenotypic heterogeneity within genetically-uniform cell populations is thought to be a universal 
phenomenon, which has received increased scrutiny in recent years with the growing awareness of its potential 
role in the persistence of microbial infections and tumours38,47,48. Typically, phenotypic heterogeneity within a 
clonal cell population is caused by gene-expression variation, arising from noise during transcription or transla-
tion, or cell cycle-, age-, or epigenetically-driven changes in expression. Epigenetic changes in the expression of 
surface antigens of P. falciparum are reported to help avoid host immune responses35. The marked heterogeneity of 
PF3D7_0629500 expression seen in this study was exploited as a novel tool to dissect the relationship between drug 
sensitivity and PF3D7_0629500 expression, at an individual cell level. We cannot infer whether PF3D7_0629500 
expression or membrane-localization is as heterogeneous in the parasite as is apparent in yeast. However, given 
the protein’s evident function in quinoline-drug transport and toxicity, any heterogeneity could have important 
implications for malaria treatment with quinolines. In bacteria, phenotypic heterogeneity is well known to create 
phenotypically resistant sub-populations – persister cells – which may re-initiate infection when antimicrobial 
Figure 7. A model of PF3D7_0629500 action. PF3D7_0629500 is proposed to facilitate cross-membrane 
diffusion of amino acids or structurally-related quinolines down concentration gradients. In the parasite, this 
would probably enable release of amino acids from the digestive vacuole or entry of drug into the vacuole. 
In yeast, where the heterologous protein localizes to the plasma membrane, PF3D7_0629500 enables drug 
uptake into cells. The T162E SNP abrogates the drug transport function, decreasing drug accumulation at the 
respective sites of action in both organisms.
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therapy is stopped48. To date there has been less work of a similar nature in Plasmodium spp., although “dormancy” 
in the parasite could have a similar effect as antimicrobial persistence49. The present results suggest a possibility 
that PF3D7_0629500 might be a good candidate for further study. Moreover, gene expression heterogeneity within 
clonal Plasmodium spp. populations could be an important gap in current drug resistance models.
Several parallels have previously been noted between PF3D7_0629500 and PfCRT, the best studied chloro-
quine resistance determinant in P. falciparum. Both are thought to serve as channel proteins on the digestive 
vacuole membrane, each containing 10 transmembrane domains27,50. Both may be involved in the transport of 
amino acids or small peptides42,51. Furthermore, inhibition of PfCRT-mediated amino acid and peptide transport 
by chloroquine has been suggested potentially to contribute to the drug’s inhibitory action51. A similar potential 
action is discussed above for PF3D7_0629500. Finally, mutations in PfCRT have been shown to alter sensitivity 
to further quinolines, such as quinine, amodiaquine and mefloquine52,53. PF3D7_0629500 expression sensitized 
yeast to all the quinoline antimalarials that were tested in this study. The evidence suggests that PF3D7_0629500 
could be important as a multi-drug sensitivity/resistance determinant in Plasmodium spp.
The weight of published evidence remains with PfCRT (in particular the K76T SNP) as the foremost marker 
of chloroquine resistance in isolates of P. falciparum. A similar strong marker has not been found with the P. vivax 
homologue (PvCRT)54,55, although there is evidence that chloroquine resistance may be conferred by changes in levels 
of PvCRT (or PvMDR1) expression56. It would be of interest to investigate the P. vivax orthologue of PF3D7_0629500 
(PVP01_1120000) as a potential resistance marker in P. vivax, where resistance to chloroquine is a growing concern57.
Among the current malaria treatment options, quinolines are commonly combined with artemisinin (or arte-
misinin derivative) in antimalarial combination treatments (ACTs). Therefore, it is worth noting that a SNP in 
PF3D7_0629500 (S258L) has previously been associated with artemisinin-resistant subpopulations of clinical P. 
falciparum isolates7. Any evolutionary selection of this SNP is not necessarily artemisinin-driven, as mutations 
conferring artemisinin resistance can be selected before a population has been exposed to the drug58. Moreover, 
given the present data and considering the prevalence of ACT therapy, we also suggest the possibility that selec-
tion for the S258L SNP could have been driven by quinolines used in combination with artemisinin.
In conclusion, rationalising previous observations with malaria parasites, the heterologous expression studies 
presented here reveal that PF3D7_0629500 activity can determine the transport and action of multiple quinoline 
drugs. Furthermore, cell-cell heterogeneity in PF3D7_0629500 activity provided a novel tool to corroborate that 
relationship, while suggesting the tantalising possibility of heterogeneous activity also in the parasite and atten-
dant implications for modelling quinoline drug resistance. Finally, the results reinforce the value of model systems 
for uncovering or substantiating novel protein functions that may have an important bearing on the spread (and 
control) of antimalarial drug resistance.
Methods
Bioinformatic analysis. The online tool HHPRED40 (available at http://toolkit.tuebingen.mpg.de/hhpred) 
was used to find orthologues of the S. cerevisiae high-affinity tryptophan transporter, Tat2, in P. falciparum. The 
Tat2 amino acid sequence from S. cerevisiae (UniProt P38967) was used as a query sequence in HHPRED using 
the Plasmodium falciparum and Saccharomyces cerevisiae databases as the target proteomes. All other options 
were at default settings. This seed query generated a multiple alignment of homologues using multiple iterations 
of PSI-BLAST. A secondary structure prediction was carried out and annotated on the final alignment using 
PSIPRED59 from which a profile Hidden Markov Model (HMM) is derived. HMM-to-HMM comparisons were 
carried out against all available HMM databases in the target proteomes to locate homologues based on similarity 
of predicted secondary structure rather than sequence alone.
Yeast strains and culture conditions. The S. cerevisiae diploid strain BY4743 (MATa/MATα his3-1/his3-1 
leu2-0/leu2-0 met15-0/MET15 LYS2/lys2-0 ura3-0/ura3-0), and isogenic deletion mutants trp1Δ and tat2Δ were 
from Euroscarf (Frankfurt, Germany). Yeast were maintained and grown in YPD medium (2% peptone, 1% yeast 
extract, 2% D-glucose; Oxoid, Basingstoke, UK), or YNB medium (0.69% yeast nitrogen base without amino 
acids; Formedium; Norfolk, UK) supplemented with 2% (w/v) D-glucose and as appropriate for plasmid selec-
tion60. Where necessary, media were solidified with 2% (w/v) agar (Sigma). To culture organisms for experiments, 
single colonies were used to inoculate broth cultures in Erlenmeyer flasks and incubated at 30 °C with orbital 
shaking at 120 rev min−1. The same procedure was used for all strains.
Growth inhibition assays. For continuous growth assays with the different yeast strains, mid/
late-exponential cultures were diluted to OD600∼0.1 and 300 µl aliquots transferred to 48-well microtiter plates 
(Greiner Bio-One; Stonehouse, UK) with antimalarial drugs added as specified and balanced for any solvent 
additions. Plates were incubated at 30 °C with shaking in a BioTek Powerwave XS microplate spectrophotometer 
and OD600 was recorded every 30 min. Cell doubling times were calculated from the linear portion of exponential 
growth. Drug concentrations giving 50% growth inhibition (IC50 values) were determined from doubling-time 
data at different drug concentrations. Antimalarial drugs used were amodiaquine dihydrochloride dihydrate 
(AMQ), chloroquine diphosphate salt (CQ), mefloquine hydrochloride (MQ) and quinine dihydrochloride (QN) 
(Sigma). Drugs were dissolved in water except quinine and mefloquine which were prepared in 70% (v/v) ethanol 
stock solutions, diluted to 0.5% final ethanol concentration for experiments. Ethanol at 0.5% has no effect on 
yeast viability and was balanced in relevant control incubations. Tryptophan additions were from stock solutions 
of 0.5 M L-tryptophan (Sigma) prepared in 1 M NaOH. NaOH (6 mM) was included in relevant control incu-
bations to balance NaOH carry-over from the tryptophan stock solution. For assays based on colony forming 
ability, FACS-sorted cell subpopulations (see below) were diluted in PBS to OD600∼5 × 10−5 (∼1500 cells ml−1) 
and 200 µl aliquots spread-plated to YPD agar plates supplemented with QN as specified. Colony forming units 
(CFUs) were counted after 4 d incubation at 30 °C.
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Heterologous expression of PF3D7_0629500 and Introduction of SNPs. A yeast-codon optimised 
PF3D7_0629500 gene cloned in the pUC57 vector was a kind gift from Enrique Salcedo-Sora (Liverpool Hope 
University). For expression in yeast, NotI and PmeI sites were added to the 5′ and 3′ termini of the PF3D7_0629500 
ORF by PCR and the product ligated between these restriction sites in the pCM190 vector61. This placed the ORF 
under the control of the doxycycline-regulatable tetO promoter. To introduce a T162E SNP into PF3D7_0629500, 
the Q5 site-directed mutagenesis kit was used according to the manufacturer’s instructions [New England Biolabs 
(NEB); Hitchin, UK]. Introduction of the SNP was verified by sequencing. Recombinant plasmids were trans-
formed into S. cerevisiae using the lithium acetate method62. To tag PF3D7_0629500 and PF3D7_0629500T162E 
with GFP, BstBI and AscI sites were added to the 5′ and 3′ termini of the relevant ORF by PCR and the product 
ligated between these restriction sites in the pFA6a-GFP(S65T)-His3MX6 vector63. The EGFP cassette with a frag-
ment of the PF3D7_0629500 or PF3D7_0629500T162E ORF up to its 3′ BlpI digestion site was then PCR amplified 
with the addition of a 5′ SfiI site and ligated in frame to pCM190-PF3D7_0629500. Primer sequences are available 
on request. Transformed yeast were grown on YNB medium with appropriate supplements for selection. All DNA 
cloning and genetic manipulations were performed in Escherichia coli XL1-blue cells. PCR, restriction digests and 
ligations were carried out using standard protocols64.
RNA extraction and quantitative RT-PCR (qRT-PCR). mRNA from specified genes in plasmid-transformed S. 
cerevisiae BY4743 was quantified by qRT-PCR exactly as described previously65, except that RNA was isolated by the “hot 
phenol” technique then treated with Amplification Grade DNase I (Sigma-Aldrich, St. Louis, MO), and 25 ng cDNA with 
175 nM gene-specific primers (sequences available on request) were used in the PCR reactions. PCRs were carried out for 
40 cycles; denaturation at 95 °C for 15 s, annealing/extension at 60 °C for 30 s. Melting-curve analysis confirmed a single 
PCR product. Amplification was quantified from a standard curve constructed from reactions with defined genomic DNA 
concentrations.
Fluorescence microscopy and FACS. For examination of GFP fluorescence by microscopy and flow 
cytometry, exponential-phase yeast cells were washed with PBS, and imaged with a DeltaVision Elite micro-
scope (GE Healthcare Life Sciences, UK) equipped with a Photometrics CoolSnap HQ2 camera (Photometrics, 
USA), or analysed with a Beckman Coulter FC500 cytometer. Staining for ∼5 min with FM4-64 (SynaptoRed 
reagent; Calbiochem, EMD Biosciences, San Diego, CA) was performed as described previously34. Microscopic 
images were acquired with a 100 × 1.4 NA objective lens. GFP fluorescence was captured using the FITC filter 
set, and FM4-64 using the TRITC filter for excitation and the Cy-5 filter for emission; the Quad polychroic was 
used for both channels. Exposure times were the same for the different strains; 0.4 s and 0.05 s for the FITC and 
Cy-5 channels, respectively. Images were collected in a single z-plane. Images, line profiles and landmarks were 
produced in Fiji (https://imagej.net/Fiji) and Igor Pro (Wavemetrics, USA) and images assembled in Inkscape 
(http://www.inkscape.org/). To FACS-sort cells, yeast expressing PF3D7_0629500-GFP were harvested by cen-
trifugation (3,220 g, 3 min) and resuspended in PBS at OD600∼2.0, before gating and sorting with a Beckman 
Coulter MoFlo XDP flow cytometer, equipped with a 488 nm laser. Emitted GFP fluorescence was collected using 
a 529/28 nm band pass filter. FACS-sorted cell subpopulations were diluted in PBS and spread to YPD agar as 
described above.
Preparation of protein extracts and western blotting. Cells were collected by centrifugation, washed 
serially with cold water and lysis buffer (50 mM Tri-HCl, 500 mM NaCl, pH 7.4, supplemented with protease 
inhibitors: 1 mM PMSF, 4 mM benzamidine hydrochloride, 2.5 mM EDTA, pH 8) then disrupted with glass 
beads66. Lysates were treated with 1% Triton X-100 on ice for 30 min and then with cracking buffer (8 M Urea, 5% 
(w/v) SDS, 40 mM Tris-HCl pH 6.8, 0.1 mM EDTA, 0.4 mg/ml bromophenol blue) at 37 °C for 10 min followed 
by incubation at 95 °C for a further 10 min. For western blotting, proteins were separated by electrophoresis on 
10% (w/v) NuPAGE Bis-Tris gels (Life Technologies) before transfer to nitrocellulose membrane (GE Healthcare). 
Protein loading was shown by staining with Ponceau S (Sigma). Immunodetection of GFP tagged proteins was 
with anti-GFP primary antibody (1:1000 dilution; Roche) and poly horseradish peroxidase (poly HRP) conju-
gated goat anti-mouse antibody (1:10000 dilution; Thermo Scientific). GFP tagged proteins were detected with 
an electrochemiluminescence HRP kit (Pierce) and imaged using a Chemidoc XRS (Bio-Rad). Protein band 
intensities were quantified with ImageJ software.
Assays of drug uptake. Quinine uptake was assayed essentially as described previously67, except that 
quinine absorbance at 350 nm31 was measured instead of quinine fluorescence. Briefly, overnight cultures were 
diluted to OD600 0.1 in fresh YPD medium and cultured for a further 4 h with shaking. Quinine was added to 
a final concentration of 4 mM and cells incubated at 30 °C, 120 rev min−1. At intervals, cells were harvested by 
centrifugation (3,220 g, 3 min), washed three times with ice cold water and resuspended in 10% (w/v) perchloric 
acid, 2 M sodium methanesulfonate together with an equal volume of acid-washed glass beads (425–600 µm, 
Sigma). Cells (∼3.7 × 108 in 800 μl) were lysed by 3 × 1-min vortexing with beads interspersed with 1 min incu-
bations on ice, centrifuged at 16,060 g, 5 min, before 20 μl supernatant (corresponding to lysate from ∼1 × 107 
cells) was diluted with 180 μl lysis buffer and A350 measured with an Ultrospec 2000 UV/visible spectrophotom-
eter (Amersham Pharmacia Biotech; Amersham, UK). Values for A350 were normalised against OD600 determi-
nations taken just before cell lysis. (The OD600 determinations provided estimates of the cell concentrations.) 
Chloroquine uptake by cells was estimated using a fluorescently-labelled chloroquine molecule, LynxTag-CQ™ 
Green (BioLynx Technologies), as described previously68. Fluorescence from cellular LynxTag-CQ™ Green was 
measured with a Beckman Coulter FC500 flow cytometer, with excitation at 488 nm. Cell autofluorescence was 
subtracted.
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Data availability. No large datasets were generated or analysed during the current study. Other data are 
available from the author on reasonable request.
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